Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The proposed sale is expected to close in the third quarter, subject to approval by the U.S. Bankruptcy Court for the Eastern ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

The deal would put the DNA data of millions of customers in the hands of a pharmaceutical company, which hopes to supercharge its efforts to mine genetic data for insights in crafting novel medicines.

Wall Street stocks edged higher Monday (May 19) after shrugging off a spike in US Treasury bond yields following Moody's ...

Health-care companies rose as some beaten-down stocks recouped some of their losses. UnitedHealth Group rose by more than 7%, but remain more than one-third lower for the year to date. Similarly, ...

Regeneron Pharmaceuticals Inc. was the successful bidder for 23andme Holding Co.’s personal genome service, total health and ...